Pagoclone: Phase II data; Phase III for panic disorder

In a placebo-controlled Phase II trial of Pagoclone in 200 patients with GAD, Pagoclone patients had a mean HAM-A score that was 2.3 points lower than placebo patient scores after 3 weeks (p=0.033); 3...